Treatment with pyrotinib-based therapy in lapatinib-resistant HER2-positive metastatic breast cancer: a multicenter real-world study

Treatment with pyrotinib-based therapy in lapatinib-resistant HER2-positive metastatic breast cancer: a multicenter real-world study

Background: Tyrosine kinase inhibitors (TKIs) are effective for treating human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. However, therapies subsequent to TKI progression remain controversial, and effective treatments for TKI resistance are urgently needed. We evalu...

Full description

Bibliographic Details
Main Authors: Yijia Hua, Wei Li, Nan Jin, Dongyan Cai, Jie Sun, Chunxiao Sun, Fan Yang, Xinyu Wu, Xiang Huang, Biyun Wang, Yongmei Yin
Format: Article
Language:English
Published: SAGE Publishing 2022-03-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359221085232

Internet

https://doi.org/10.1177/17588359221085232

Similar Items